Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS – Sarepta Therapeutics

CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jul. 25, 2025– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administrati…

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com